Results 141 to 150 of about 26,261 (211)

Successful Use of Glucagon-Like Peptide-1 Receptor Agonist in a Patient With Recurrent Hypertriglyceridemia-Induced Pancreatitis. [PDF]

ACG Case Rep J
Guralwar C, Mitsuhashi S, Ashkar M, Chedid VG.   +3 more
europepmc   +1 more source

Glucagon-like peptide-1 receptor agonist use and clinical outcomes after lung transplantation: A single-center cohort study. [PDF]

JHLT Open
Miyashita Y, Kaiho T, Reichenbach R, Yagi Y, Arunachalam A, Kurihara C.   +5 more
europepmc   +1 more source

Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli‐D Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To compare the efficacy and safety of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with insulin degludec plus insulin aspart (IDegAsp) by baseline age, Type 2 diabetes (T2D) duration and glycated haemoglobin (HbA1c) in the Soli‐D study.
Saichun Zhang, Yunjuan Gu, Yu Cheng, Ying Hu, Bing Li, Agustina Alvarez, Felipe Lauand, Lydie Melas‐Melt, Minlu Zhang, Yini Jiang, Qin Du, Lei Kang, Yiming Mu, Weijun Gu, Hongyu Kuang   +14 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy-a phase 2 randomized trial. [PDF]

Nat Commun
Wang H, Ko H, Leung TW, Huang J, Sai J, Liang Y, Li H, Zhang J, Cao Q, Zang W, Li Y, Ma SH, Lui WT, Choi J, Chan C, Wong J, Kwok AJ, Ma K, Fan F, Chan A, Ip V, Leung H, Soo Y, Wong KT, Lai B, Chu CM, Leung HS, Hui A, Cheung T, Abrigo J, Li SH, Chan L, Yeung J, Pan S, Yip T, Lui LT, Hung T, Tsang SF, Leng X, Lam B, Mok VCT, Chan RHM, Nguyen TN, Hu W, Che F, Ip BY.   +45 more
europepmc   +1 more source

Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6‐Month Claims Database Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Tirzepatide is a once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) approved in the US for the treatment of Type 2 diabetes (T2D), weight loss and obstructive sleep apnoea. This study aimed to assess the utilisation and effectiveness of tirzepatide among individuals in a large ...
Theresa Hunter Gibble, Malvika Venkataraman, Donna Mojdami, Carlos Vallarino, Grace Stockbower, Michael Grabner, Mythili Ananth, Karishma Desai   +7 more
wiley   +1 more source

Combined Glucagon-like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Use and Survival. [PDF]

AACE Endocrinol Diabetes
Reule S, Pickthorn S, Drake T, Ishani A, Foley R.   +4 more
europepmc   +1 more source

Severity of Cardiovascular Autonomic Neuropathy Is Linked to Increasing Levels of Circulating Proinflammatory Cytokines

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardiovascular autonomic neuropathy (CAN) is a severe form of diabetic neuropathy affecting approximately one in five people with diabetes and is a major predictor of cardiovascular mortality. Low‐grade inflammation may contribute to CAN development, but the exact inflammatory factors associated with CAN remain unclear.
Michelle Damgaard, Marietta Kokla, Rebekka H. Gerwig, Hatice Isik Mizrak, Sofie Korsgaard Hecquet, Tik Muk, Gurjeet Kaur, Birgitte Brock, Christian Stevns Hansen, Joachim Størling   +9 more
wiley   +1 more source

Bridging Efficacy and Adherence in Glucagon-Like Peptide-1 Receptor Agonist Therapy: The Emerging Role of Oral Agents. [PDF]

Diabetes Metab J
Wang SY, Stofer R, Wang H, Brent GA, Shi L, Cai Y, Roosan M, Moin T.   +7 more
europepmc   +1 more source

Real‐World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Tirzepatide has demonstrated substantial weight‐loss efficacy in clinical trials, but real‐world evidence from routine digital prescribing remains limited. Methods We conducted a retrospective cohort study of adults initiating tirzepatide for obesity via a UK digital prescribing service between March 2024 and July 2025. Linked order‐
Onayomi Rosenior‐Patten, Zoe Lees, Rebecca Rowe, Safia Hussain, Ehtasham Ahmad, Edward Brooke, Sophie Dix, Catriona Maybury   +7 more
wiley   +1 more source

Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity. [PDF]

J Med Chem
Wu B, Falsey JR, Netirojjanakul C, Herberich B, Holder JR, Sham K, Aral J, Forsythe N, Walker KW, Lu SC, Hager T, Stanislaus S, Komorowski R, Atangan L, Achmatowicz M, Romanini D, Weeraratne D, Miranda LP, Véniant MM, Cheng Y.   +19 more
europepmc   +1 more source